The Ben & Catherine Ivy Foundation Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial
2014
NCT02207010
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (2)

mk-1775 (1 trial)

personalized neoantigen vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2